All Stories

  1. Reply of the authors of the Continuing Medical Education article to Dr. Jaison Barreto and Dr. Laila Laguiche
  2. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach
  3. Mycobacterium leprae-Specific Antibodies in Multibacillary Leprosy Patients Decrease During and After Treatment With Either the Regular 12 Doses Multidrug Therapy (MDT) or the Uniform 6 Doses MDT
  4. Development of a nanogold slot blot inhibition assay for the detection of antibodies against bovine herpesvirus type 1
  5. Phylogenomics and antimicrobial resistance of the leprosy bacillus Mycobacterium leprae
  6. Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients
  7. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients
  8. Whole genome sequencing distinguishes between relapse and reinfection in recurrent leprosy cases
  9. Leprosy reactions: The predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR)
  10. Fatores associados à coinfecção tuberculose e HIV: o que apontam os dados de notificação do Estado do Amazonas, Brasil, 2001-2012
  11. Could Mycobacterium leprae Infection Be an Occupational Disease? A Survey in Healthcare Workers From an Endemic Area in the Amazonian Region
  12. Description of Leprosy Classification at Baseline Among Patients Enrolled at the Uniform Multidrug Therapy Clinical Trial for Leprosy Patients in Brazil
  13. Temporal distribution of tuberculosis in the State of Amazonas, Brazil
  14. Multidrug-resistant tuberculosis in the Amazonas State, Brazil, 2000–2011
  15. Evaluation of a rapid serological test for leprosy classification using human serum albumin as the antigen carrier
  16. Tuberculosis Infection Control: Potential Benefit of a New Rapid Tuberculosis Test in a Human Immunodeficiency Virus/AIDS Reference Hospital
  17. Phage Display and Synthetic Peptides as Promising Biotechnological Tools for the Serological Diagnosis of Leprosy
  18. Mycobacterium tuberculosis Infection in Young Children: Analyzing the Performance of the Diagnostic Tests
  19. Primary drug resistance among pulmonary treatment-naïve tuberculosis patients in Amazonas State, Brazil
  20. Phenolic Glycolipid-I Does Not Cross-react With Visceral Leishmaniasis Sera in a Brazilian Subset
  21. Serology with ML Flow test in health professionals from three different states of Brazil
  22. Increased Sensitivity in Diagnosis of Tuberculosis in HIV-Positive Patients through the Small-Membrane-Filter Method of Microscopy
  23. Historical analysis of the records of sylvan yellow fever in the State of Amazonas, Brazil, from 1996 to 2009
  24. Evaluation of New Strategies for the Diagnosis of Tuberculosis Among Pediatric Contacts of Tuberculosis Patients
  25. Primary multidrug-resistant tuberculosis and its control implications in the State of Amazonas, Brazil: report of 3 cases
  26. Impact of PGL-I Seropositivity on the Protective Effect of BCG Vaccination among Leprosy Contacts: A Cohort Study
  27. Factors Associated with Tuberculosis Treatment Default in an Endemic Area of the Brazilian Amazon: A Case Control-Study
  28. Correlation between ELISA and ML Flow assays applied to 60 Brazilian patients affected by leprosy
  29. The additional benefit of the ML Flow test to classify leprosy patients
  30. Associação entre reação hansênica após alta e a carga bacilar avaliada utilizando sorologia anti PGL-I e baciloscopia
  31. Associação do teste sorológico ML Flow com a baciloscopia
  32. Avaliação da concordância entre exames clínicos e laboratoriais no diagnóstico da hanseníase
  33. Sorologia rápida para hanseníase (teste ML Flow) em pacientes dimorfos classificados como paucibacilares pelo número de lesões cutâneas: uma ferramenta útil
  34. Sorologia da hanseníase utilizando PGL-I: revisão sistemática
  35. Sorologia PGL-I na hanseníase
  36. Pesquisa de anticorpos anti PGL-I através de ELISA em tatus selvagens do Brasil
  37. Fatores de risco para a soropositividade do ML Flow em pacientes com hanseníase
  38. Soroprevalência do teste ML Flow em contatos de hanseníase de Minas Gerais
  39. A influência do teste sorológico ML Flow na classificação da hanseníase
  40. A relação entre soroprevalência de anticorpos contra o glicolipídeo fenólico-I entre crianças em idade escolar e endemicidade da hanseníase no Brasil
  41. Comportamento dos testes sorológicos ML Flow e ELISA (PGL-I) em áreas endêmica e não endêmica de hanseníase
  42. O uso da sorologia como ferramenta adicional no apoio ao diagnóstico de casos difíceis de hanseníase multibacilar: lições de uma unidade de referência
  43. High prevalence of vasomotor reflex impairment in newly diagnosed leprosy patients
  44. Postgenomic Approach To Identify Novel Mycobacterium leprae Antigens with Potential To Improve Immunodiagnosis of Infection
  45. Simple and Fast Lateral Flow Test for Classification of Leprosy Patients and Identification of Contacts with High Risk of Developing Leprosy
  46. Dipstick assay to identify leprosy patients who have an increased risk of relapse
  47. Simple dipstick assay for semi-quantitative detection of neopterin in sera
  48. The use of whole blood in a dipstick assay for detection of antibodies to Mycobacterium leprae: a field evaluation